—Data Presented at 2022 EASL International Liver
ConferenceTM and First International Extracellular
Matrix Pharmacology Congress—
TEL
AVIV, Israel, June 27,
2022 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibrotic and inflammatory diseases with high unmet need, today
reported on two recent presentations at important scientific
meetings. The presentations included preclinical data that support
the role of the soluble protein CCL24 in the pathophysiology of
liver diseases such as primary sclerosing cholangitis (PSC), and
also indicate that Chemomab's CCL24 neutralizing antibody CM-101
demonstrates translatable patterns of extracellular matrix (ECM)
remodeling in preclinical and clinical studies.
At EASL: The International Liver Congress™ 2022, Chemomab
presented data1 from a combination of single-cell and
spatial transcriptomics methods that enabled an in-depth analysis
of relevant subpopulations and pathways regulated by CCL24 in
fibroinflammatory liver disease. The analysis revealed unique
resident liver macrophage subpopulations as the major source of
CCL24 in the injured peribiliary area in an experimental PSC model.
The analysis also showed that treatment with CM-101 interfered with
core PSC pathways, including inhibiting ECM-related pathways and
the recruitment and presence of monocytes and macrophages.
At the First International Extracellular Matrix Pharmacology
Conference, Chemomab presented clinical and animal model
data2 demonstrating that treatment with its CCL24
neutralizing antibody CM-101 attenuates remodeling of ECM key
proteins. ECM deposition is known to be affected by fibroblast
activation and epithelial cell activity, key cell populations that
have been shown to be involved in the pathophysiology of PSC and
that are closely related to CM-101's mechanism of action.
Importantly, this dataset supports the translation of these results
from relevant animal models into the design of Chemomab's clinical
studies assessing CM-101 as a potential treatment for PSC,
including potentially applying findings using experimental models
of ECM remodeling in the liver to the use of a translatable profile
of serum biomarkers in patients.
"We welcome the opportunity to present validating data on the
central role of CCL24 in the pathophysiology of fibroinflammatory
liver disease and the corresponding ability of CM-101 to attenuate
key biomarkers associated with this pathophysiology," noted
Adi Mor, PhD, co-founder and Chief
Scientific Officer of Chemomab. "These studies are valuable for
informing our clinical trials in PSC and other disorders, and for
further highlighting the significant potential of our unique
approach."
1 - Combination of Whole Liver Single Cell RNA Sequencing and
Spatial Transcriptomics Reveals Specific Cell Sub-Populations and
Pathways Regulated by CCL24, Abstract Identifier: OS02,
June 23, 2022
2 - CCL24 Inhibition by CM-101 Attenuates Extracellular
Matrix and Fibrotic Biomarkers in Both Patients and
Experimental Murine Models, Abstract ID:155, Udi
Gluschnaider, Amnon Peled,
Michal Segal-Salto, Avi Katav, Omer
Levi, Adi Mor, Ophir Hay, Inbal Mishalian,
Devorah Olam and Raanan Greenman, June 23, 2022
Click here to view the Chemomab EASL 2022 presentation and
click here to view the Chemomab First International ECM
Congress poster.
About CM-101
CM-101 is a monoclonal antibody
that neutralizes the soluble protein CCL24, a cytokine family
member that can trigger self-reinforcing inflammatory and fibrotic
pathways implicated in a number of serious progressive diseases. In
extensive preclinical studies, Chemomab has validated CCL24's role
as a target while establishing CM-101 proof-of-concept in studies
in multiple disease models and patient samples. CM-101 was safe and
well tolerated in Phase 1 clinical trials and it improved liver
biomarkers, decreased liver stiffness and demonstrated a favorable
PK and target engagement profile in patients with nonalcoholic
fatty liver disease. CM-101 is currently in two Phase 2 trials in
patients with primary sclerosing cholangitis and liver fibrosis. A
third Phase 2 trial in systemic sclerosis is expected to start
before year-end. For more information, visit chemomab.com/r-d/.
Forward Looking
Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These forward-looking statements
include, among other things, statements regarding the clinical
development pathway for CM-101; the future operations of Chemomab
and its ability to successfully initiate and complete clinical
trials and achieve regulatory milestones; the nature, strategy and
focus of Chemomab; the development and commercial potential and
potential benefits of any product candidates of Chemomab; and that
the product candidates have the potential to address high unmet
needs of patients with serious fibrosis-related diseases and
conditions. Any statements contained in this communication that are
not statements of historical fact may be deemed to be
forward-looking statements. These forward-looking statements are
based upon Chemomab's current expectations. Forward-looking
statements involve risks and uncertainties. Because such statements
deal with future events and are based on Chemomab's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of Chemomab could
differ materially from those described in or implied by the
statements in this presentation, including: risks related to
Chemomab's ability to effectively implement the revised clinical
strategy and its ability to achieve the anticipated results; risks
related to the projections and associated benefits in pursuing the
contemplated changes to the clinical strategy; risks associated
with the ongoing transitions of certain of our executive officers,
including Chemomab's new Chief Executive Officer; the uncertain and
time-consuming regulatory approval process; risks related to
Chemomab's ability to correctly manage its operating expenses and
its expenses; Chemomab's plans to develop and commercialize its
product candidates, focusing on CM-101; the timing of initiation of
Chemomab's planned clinical trials; the timing of the availability
of data from Chemomab's clinical trials including any potential
delays associated with Chemomab's contemplated revised clinical
strategy; the timing of any planned investigational new drug
application or new drug application; Chemomab's plans to research,
develop and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of Chemomab's product candidates; Chemomab's
commercialization, marketing and manufacturing capabilities and
strategy; Chemomab's ability to protect its intellectual property
position; and the requirement for additional capital to continue to
advance these product candidates, which may not be available on
favorable terms or at all. Additional risks and uncertainties
relating to Chemomab and its business can be found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based, except to the extent required by applicable
law.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical-stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases. It is currently in Phase 2
trials for primary sclerosing cholangitis and liver fibrosis, with
a Phase 2 trial in systemic sclerosis expected to begin in late
2022. For more information, visit chemomab.com.
Contacts:
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President,
Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara@chemomab.com
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 917-734-7387
ir@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-presents-data-further-supporting-the-mechanism-of-action-and-potential-efficacy-of-cm-101-in-primary-sclerosing-cholangitis-301575503.html
SOURCE Chemomab Therapeutics, Ltd.